SARS-CoV-2 Spike-Binding Antibody for Targeted Virus Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no specific therapeutic agents, prophylactic agents, or diagnostic kits available for SARS-CoV-2, and existing treatments for COVID-19 lack clear mechanisms of action and often come with severe side effects.
Innovation Solution
Development of a binding molecule that can bind to and neutralize the spike protein of SARS-CoV-2, including an immunoconjugate, nucleic acid molecule, expression vector, and cell line, with applications in diagnostic kits and therapeutic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic agents (antiviral drugs, interferon, plasma therapy) are used to treat COVID-19, then some therapeutic effect is observed, but severe side effects occur and the mechanism of action is unclear
Solution Approach 1:
The patent uses a humanized antibody as an intermediary substance that specifically binds to the spike protein of SARS-CoV-2. This antibody acts as a mediator between the immune system and the virus, blocking viral entry into cells without the severe side effects associated with conventional antiviral drugs and interferon therapy
Solution Approach 2:
The patent changes the fundamental parameter of therapeutic approach from non-specific antiviral mechanisms (with severe side effects) to highly specific antigen-antibody binding. The humanized antibody provides targeted neutralization of SARS-CoV-2 through specific binding to the spike protein, eliminating the need for broad-spectrum antiviral mechanisms that cause severe side effects
2Reliability
If plasma therapy is used to treat severely ill COVID-19 patients, then therapeutic effect is observed, but the mechanism is unclear and risk is high
Solution Approach 1:
The patent extracts and isolates the specific protective component (neutralizing antibody) from complex plasma therapy. Instead of using whole plasma with unknown mechanisms and high risk, the invention isolates the humanized antibody that specifically binds to SARS-CoV-2 spike protein, providing a defined and controllable therapeutic agent with known mechanism of action
Solution Approach 2:
The humanized antibody serves as a purified intermediary substance that mediates the therapeutic effect by specifically binding to the spike protein. This replaces the complex plasma therapy with a defined molecular mediator whose mechanism of action (blocking viral entry through spike protein binding) is clearly understood
3Reliability
If existing antiviral drugs are used for COVID-19 treatment, then some therapeutic effects are achieved, but clear mechanism of action has not been proven
Solution Approach 1:
The humanized antibody provides a clear mechanistic intermediary that physically binds to the spike protein, blocking viral entry into host cells. This antibody-mediated neutralization mechanism is well-understood and provides clear information about how the therapeutic effect is achieved, unlike existing antiviral drugs with unclear mechanisms
Solution Approach 2:
The patent changes the therapeutic mechanism from unknown antiviral actions to well-defined antigen-antibody binding. The humanized antibody provides clear mechanistic information through its specific binding to the spike protein, enabling precise understanding of neutralization without the information loss associated with conventional antiviral drugs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecule effectively neutralizes SARS-CoV-2, including mutant strains, and is used in diagnostic kits and therapeutic compositions to treat and prevent COVID-19, without adverse effects like antibody-dependent enhancement.
Implementation Method 1
a binding molecule which binds to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), and more particularly binds to a spike protein (S protein) on the surface of SARS-coronavirus-2
Data Source
AI summary
The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).